Psychiatric medication management for Delray Beach — residential-level optimization, 0 minutes away.

RECO Immersive's residential campus sits at 140 NE 4th Avenue in downtown Delray Beach, a five-minute drive from Lake Ida, Tropic Isle, and Pineapple Grove. Psychiatry is embedded in the daily clinical rhythm rather than scheduled around it: observed adherence, weekly lithium and valproate levels during titration, and pharmacology coordinated with any concurrent rTMS or esketamine course at RECO Health. Discharge includes a documented medication plan that transfers cleanly to outpatient care.

RECO Immersive’s residential campus at 140 NE 4th Avenue sits one block off Atlantic Avenue and a five-minute walk from the ocean, placing intensive psychiatric care inside the same Delray Beach neighborhoods clients already know — from Pineapple Grove down through Osceola Park and out toward the Beach District. For adults whose depression, PTSD, bipolar disorder, or anxiety has stopped responding to weekly outpatient visits, the difference isn’t distance but density: psychiatry embedded in the daily clinical rhythm rather than scheduled around it. That structure is what makes residential-level psychiatric medication management a categorically different intervention from what a monthly prescriber can deliver.

What observed adherence and daily monitoring change

Outpatient pharmacology is built on inference. Whether the client actually took the sertraline this morning, whether the quetiapine goes down at bedtime, whether the lithium dose that looked right at the last visit is still being taken at the prescribed schedule — these are estimated from self-report and pill counts. Both are unreliable in mood and psychotic disorders, and both fail exactly when the medication matters most: during titration, during a mixed-state crisis, or when a partial response could tip into full remission with the right adjustment.

In residential care, adherence is observed. Nursing staff witness every administration, document time and dose, and log same-day tolerability data — sleep, appetite, akathisia, activation, sedation, GI effects. For narrow-therapeutic-window agents like lithium and valproate, and for atypicals like olanzapine and aripiprazole where metabolic and extrapyramidal signals matter, the observed record is what the prescriber actually titrates against.

The clinical consequence is speed. Side effects that would take two weeks to surface in outpatient care — by which point most clients have quietly discontinued — surface the same evening and get addressed at the next round. A regimen that would need three outpatient visits to optimize can be optimized inside a two-week window.

Comprehensive lab monitoring during residential stay

Admission labs run on day one: CBC, CMP, TSH with reflex, B12, folate, vitamin D, lipid panel, HbA1c, urinalysis, urine drug screen, and urine pregnancy where indicated. Baseline EKG is standard for any client entering on QT-prolonging agents, or when cardiovascular risk warrants it before initiating a new antipsychotic.

Medication-specific monitoring runs on a clinically driven cadence rather than a scheduling-driven one. Lithium levels are drawn weekly during titration and again after any dose change, with maintenance target trough between 0.6 and 1.0 mEq/L. Valproate follows the same principle. Metabolic panels bookend the stay for anyone on an atypical antipsychotic, with weight, waist circumference, and fasting glucose tracked in between.

This is what residential adds that outpatient cannot: labs drawn on the same site where the medication is prescribed and administered, results reviewed by the psychiatry team before the next dose, and adjustments made within the same treatment day rather than at the next available appointment slot.

Coordination with concurrent interventional treatment

Many Immersive clients are on active interventional protocols at RECO Health — rTMS delivered at 120% of resting motor threshold, 3,000 pulses per session over a standard course for treatment-resistant depression, or IV ketamine and intranasal esketamine for clients meeting TRD criteria. The psychiatry team runs both the oral regimen and the interventional plan rather than negotiating across two independent prescribers.

That matters concretely. Benzodiazepines blunt rTMS response and are tapered where clinically safe before the course begins. Agents that raise seizure-threshold considerations are reviewed for TMS candidacy. Around ketamine infusions, dosing timing of anxiolytics and mood stabilizers is coordinated to protect the dissociative window without collapsing baseline stabilization. Between infusions, PHQ-9 and GAD-7 are re-administered on the schedule the interventional protocol specifies, and oral antidepressant selection is informed by the response trajectory rather than added independently.

Interventional gains hold only when the pharmacology plan supports them. Running both under one team is what allows that.

What the first 72 hours look like

Admission begins with a full psychiatric evaluation: DSM-5 differential, PHQ-9 for depression severity, GAD-7 for anxiety, ASRS where adult ADHD is on the table, YBOCS for OCD-spectrum presentations, PCL-5 for trauma symptoms. Substance use is screened across ASAM Criteria dimensions, and where alcohol or benzodiazepine dependence is present, CIWA-Ar governs the first days. COWS drives opioid-withdrawal management where indicated, with buprenorphine induction or comfort protocol as clinically appropriate.

By day three, the psychiatry team, the primary therapist, and the case manager have converged on a working formulation and an initial treatment plan integrating pharmacology with the therapy modalities the case calls for — CBT for depressive cognition, DBT skills for emotion dysregulation, EMDR or prolonged exposure for trauma, ACT for values-based behavioral activation, and motivational interviewing where ambivalence about treatment itself is a factor.

The medication plan the client leaves with

Discharge from Immersive is a document, not a handshake. Clients leave with a written medication plan that specifies current regimen, dose rationale, response data during stay, next-step contingencies, monitoring schedule, and target labs. The plan transfers cleanly to the RECO Health outpatient team, to the client’s home prescriber, or to a new PCP-psychiatry combination in Delray Beach or wherever the client is going.

The client also leaves knowing what they’re on and why. A client discharging on aripiprazole plus sertraline knows which agent addresses which symptom cluster, what the six-week trajectory should look like, which side effects warrant a call, and what the next PHQ-9 target is. A client on lithium knows their maintenance trough, their monitoring schedule, and the interaction profile with NSAIDs, ACE inhibitors, and dehydration.

That handoff clarity is what makes residential pharmacology gains hold once the client is back in outpatient care.

Insurance and admissions from Delray Beach

RECO Immersive is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans. Admissions runs a verification of benefits before intake so the client knows per-day coinsurance, deductible position, and expected out-of-pocket for a typical 28-day stay before arriving. Residential mental health is generally covered under mental health parity, though authorization is level-of-care driven and requires documentation of medical necessity — active symptom severity, prior outpatient failure, or safety concern.

For Delray Beach residents, admission is often same-day. The campus is a short drive from Lake Ida, Tropic Isle, the Beach District, and Osceola Park — logistics that matter when someone is in crisis and can’t tolerate a long transport or an out-of-state placement that fractures family involvement.

Serving residents of: Pineapple Grove, Lake Ida, Tropic Isle, Beach District, Osceola Park.